The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.
about
CAR models: next-generation CAR modifications for enhanced T-cell functionNew Strategies for the Treatment of Solid Tumors with CAR-T CellsAdoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptorsStrategies for combining immunotherapy with radiation for anticancer therapyRecent advances in T-cell engineering for use in immunotherapySmart CARs engineered for cancer immunotherapyDesigning chimeric antigen receptors to effectively and safely target tumorsAn Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other CancersPreserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adultsEqual opportunity CAR T cells.5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells.Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.Versatile strategy for controlling the specificity and activity of engineered T cells.Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy.Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cellsChimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacySleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptorsAnti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model.CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignanciesChimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer.CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemiaFully human CD19-specific chimeric antigen receptors for T-cell therapy.In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-SpacerCAR-T Cell Therapy for Lymphoma.Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.Comparison of naïve and central memory derived CD8(+) effector cell engraftment fitness and function following adoptive transfer.CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patientsClinical responses with T lymphocytes targeting malignancy-associated κ light chains.T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.Chimeric antigen receptor-redirected T cells return to the benchEngineering CAR-T cells: Design concepts.CD19 chimeric antigen receptor T cell therapy for haematological malignancies.
P2860
Q26745600-1EBFBE5F-E633-43EE-A0AB-B34DAF5A18A0Q26748500-983D0894-D80C-4E86-84BD-AFE6D4F1C6DDQ26795540-CD8C1E70-D9A1-47C8-A64F-62AB5FFA9187Q26796675-ABAC8F38-195C-4980-9538-5B07EFB56ADAQ28080312-F1FBFF04-A635-4DC3-BD55-E85B52B39181Q28087236-06366C48-24A5-4A4D-A65B-680B0BB0BFFDQ28088526-7FFE40AF-5914-4D45-8155-09057BBDF36DQ28551080-6C35ED2B-1045-4259-B857-22779BEE4F8AQ30764873-8A6DE46F-10D6-488C-BBD1-CD064AFF3B08Q33827997-3BEA44BB-FE35-452B-AD4F-EB43F3CF3515Q33828001-6682345B-46BD-47B9-BB67-EBE917C9DCC8Q33884816-D11CD160-9C28-4208-96CA-4767FB088669Q34044910-83F96B74-D44C-4B59-A84B-1AD73F5BA396Q34045831-6B1303A6-B382-419C-8958-77044C11C38DQ34046252-2FD574A1-7C4E-4AFC-ABAA-33BAAE1BBA93Q34517676-B2C07012-36E5-44E8-937A-80C86D0D7FB1Q34553167-1662355A-4FFA-42E6-9DFD-DB31455E5AE1Q35328354-19EB9AFC-71C1-4318-A1D8-B4A74D2EFA05Q35399080-550B8F9D-938B-453B-A153-8F9BC07D3636Q35648352-E3D85A4B-408C-41E7-8AE8-767C9392AF3EQ35690389-B55C0D17-E72F-4CB1-8DA9-E852979A93D4Q35810197-3B98A9F8-7727-4BC2-B748-D57D808DCBEAQ35811921-B7E391B0-62B2-413E-9EFE-54F63F8A7E36Q35877585-52CC60A3-1171-4055-B62B-A35F9E2CD8E4Q35904943-E39AE802-48FC-4501-A02B-4023CB1AA008Q35976599-6978E181-8F4E-469B-8090-26E40FE438F5Q35980893-7C26F73B-DA6A-4FD5-8766-EC748CA48A12Q36132731-CB82A107-BD45-4B00-814D-ED6AB5A979E4Q36279306-6B6A39C1-E046-4A6A-BFB7-DE4D02AE05F0Q36281920-17F11AF3-AA5D-4DF1-8C7E-AA86BDE4DA25Q36333154-8972B810-28E9-47BA-ADB3-43C7F503AB0BQ36519358-970D884A-E6FA-445B-B798-5FB293E1803DQ36551673-7A88DA35-98CB-4884-A8FE-668DAAFB3FF9Q36597392-55CA731B-0173-42BE-9F5C-3C8D854E3C56Q36951727-8F236AFC-EDE3-43FC-807C-5BE8CD6B4AD8Q37042225-A1912022-8DC2-47EA-B36D-9B7099DB2ED9Q37066770-B738E00E-D1E9-46F4-AA68-57C11B1F9753Q37301510-617CD10A-129B-4F68-A071-2F559DA41B71Q38290031-5ED90B33-DEA1-4139-B6E0-762057DD3379Q38370975-98E6C23F-4775-406B-A553-3CBCF8C4938E
P2860
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
The nonsignaling extracellular ...... or in vivo antitumor activity.
@ast
The nonsignaling extracellular ...... or in vivo antitumor activity.
@en
type
label
The nonsignaling extracellular ...... or in vivo antitumor activity.
@ast
The nonsignaling extracellular ...... or in vivo antitumor activity.
@en
prefLabel
The nonsignaling extracellular ...... or in vivo antitumor activity.
@ast
The nonsignaling extracellular ...... or in vivo antitumor activity.
@en
P2093
P2860
P1476
The nonsignaling extracellular ...... for in vivo antitumor activity
@en
P2093
Anne Silva-Benedict
Daniel Sommermeyer
Lingfeng Liu
Michael C Jensen
Paula L Kosasih
Stanley R Riddell
P2860
P304
P356
10.1158/2326-6066.CIR-14-0127
P577
2014-09-11T00:00:00Z